Literature DB >> 7354125

Pharmacokinetic properties of human fibroblast and leukocyte interferon in rabbits.

J Vilcek, I T Sulea, I L Zerebeckyj, Y K Yip.   

Abstract

When rabbits were given intramuscular injections of the same quantities of human leukocyte or fibroblast interferons, the former produced moderately higher levels of circulating interferon. Fibroblast interferon was not cleared faster from circulation, nor was direct inactivation by rabbit blood responsible for this difference.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7354125      PMCID： PMC273326          DOI： 10.1128/jcm.11.1.102-105.1980

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  21 in total

1.  Unexpectedly rapid action of human interferon in physiological conditions.

Authors:  F Dianzani; S Baron
Journal:  Nature       Date:  1975-10-23       Impact factor: 49.962

2.  Administration of human leukocyte interferon in herpes zoster. I. Safety, circulating, antiviral activity, and host responses to infection.

Authors:  G W Jordan; R P Fried; T C Merigan
Journal:  J Infect Dis       Date:  1974-07       Impact factor: 5.226

3.  Mass production of human interferon in diploid cells stimulated by poly-I:C.

Authors:  A Billiau; M Joniau; P De Somer
Journal:  J Gen Virol       Date:  1973-04       Impact factor: 3.891

4.  Further studies on the production of interferon by human leukocyte in vitro.

Authors:  H Strander; K Cantell
Journal:  Ann Med Exp Biol Fenn       Date:  1967

5.  Production of high-titered interferon in cultures of human diploid cells.

Authors:  E A Havell; J Vilcek
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

6.  Accentuation of production of human interferon by metabolic inhibitors.

Authors:  M Ho; Y H Tan; J A Armstrong
Journal:  Proc Soc Exp Biol Med       Date:  1972-01

7.  Circulating human interferon after intramuscular injection into animals and man.

Authors:  K Cantell; L Pyhälä; H Strander
Journal:  J Gen Virol       Date:  1974-12       Impact factor: 3.891

8.  Human chromosome 21 dosage: effect on the expression of the interferon induced antiviral state.

Authors:  Y H Tan; E L Schneider; J Tischfield; C J Epstein; F H Ruddle
Journal:  Science       Date:  1974-10-04       Impact factor: 47.728

9.  Two antigenically distinct species of human interferon.

Authors:  E A Havell; B Berman; C A Ogburn; K Berg; K Paucker; J Vilcek
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

10.  Stabilization of interferon messenger RNA activity by treatment of cells with metabolic inhibitors and lowering of the incubation temperature.

Authors:  J Vilcek; E A Havell
Journal:  Proc Natl Acad Sci U S A       Date:  1973-12       Impact factor: 11.205
View more
  5 in total

Review 1.  Differences between human alpha (leukocyte) and beta (fibroblast) interferons.

Authors:  T G Hayes
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

Review 2.  Interferon therapy: pharmacokinetic and pharmacological aspects.

Authors:  A Billiau
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

3.  Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice.

Authors:  A Billiau; H Heremans; D Ververken; J van Damme; H Carton; P de Somer
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

4.  Immunological profile of amyotrophic lateral sclerosis patients and their cell-mediated immune responses to viral and CNS antigens.

Authors:  H Bartfeld; C Dham; H Donnenfeld; L Jashnani; R Carp; R Kascsak; J Vilcek; M Rapport; S Wallenstein
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

Review 5.  The clinical application of fibroblast interferon--an overview.

Authors:  A Billiau
Journal:  Med Oncol Tumor Pharmacother       Date:  1984
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.